目的 探討胃蘇顆粒聯(lián)合鋁碳酸鎂治療反流性胃炎的臨床療效。方法 選取2015年3月-2016年3月榆林市中醫(yī)醫(yī)院收治的反流性胃炎患者80例，隨機(jī)分為對(duì)照組和治療組，每組各40例。對(duì)照組口服鋁碳酸鎂片，2片/次，3次/d。治療組在對(duì)照組基礎(chǔ)上口服胃蘇顆粒，3袋/次，3次/d。兩組患者均治療2周。觀察兩組的臨床療效，比較兩組的臨床癥狀、生活質(zhì)量、血管活性腸肽（VIP）及白細(xì)胞介素-6（IL-6）的變化。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為80.00%、95.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者臨床癥狀評(píng)分和胃食管返流疾病生活質(zhì)量（GERD-HRQL）評(píng)分均顯著降低，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的降低程度明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清VIP及IL-6水平均顯著降低，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的降低程度明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 胃蘇顆粒聯(lián)合鋁碳酸鎂治療反流性胃炎具有較好的臨床療效，可改善臨床癥狀，降低炎癥反應(yīng)，提高生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Weisu Granules combined with hydrotalcite in treatment of reflux gastritis. Methods Patients (80 cases) with reflux gastritis in Chinese Medicine Hospital of Yulin from March 2015 to March 2016 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were po administered with Hydrotalcite Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Weisu Granules on the basis of the control group, 3 bag/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the changes of clinical symptoms, quality of life, vasoactive intestinal peptide (VIP), and IL-6 in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 95.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of clinical symptoms and GERD-HRQL in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of VIP and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Weisu Granules combined with hydrotalcite has the clinical curative effect in treatment of reflux gastritis, and can improve clinical symptoms, decrease inflammatory reaction, enhance quality of life, which has a certain clinical application value.